Enanta Pharmaceuticals’ (ENTA) “Market Outperform” Rating Reiterated at JMP Securities

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a note issued to investors on Tuesday,Benzinga reports. They currently have a $21.00 price objective on the biotechnology company’s stock. JMP Securities’ target price suggests a potential upside of 271.02% from the stock’s previous close.

A number of other brokerages have also recently commented on ENTA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Up 15.5 %

Shares of Enanta Pharmaceuticals stock traded up $0.76 on Tuesday, reaching $5.66. The stock had a trading volume of 459,046 shares, compared to its average volume of 495,011. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80. The company has a 50 day moving average price of $5.94 and a 200 day moving average price of $9.68. The stock has a market capitalization of $120.73 million, a P/E ratio of -1.03 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. On average, analysts forecast that Enanta Pharmaceuticals will post -5.05 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares in the company, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 13.89% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Krensavage Asset Management LLC grew its stake in Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after acquiring an additional 246,736 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Enanta Pharmaceuticals in the third quarter valued at about $1,243,000. Point72 Asset Management L.P. purchased a new position in Enanta Pharmaceuticals during the third quarter worth about $903,000. JPMorgan Chase & Co. increased its position in shares of Enanta Pharmaceuticals by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after acquiring an additional 85,082 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Enanta Pharmaceuticals by 34.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after acquiring an additional 49,050 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.